Semaglutide vs Tirzepatide: Which Drops More Weight?

Affiliate disclosure: This article contains affiliate links, and allcheminfo.com may earn a commission if you use them, at no extra cost to you. This article is informational and is not medical advice — decisions about prescription medication should be made with a qualified clinician.

Behind every blockbuster GLP-1 brand name is one of two molecules. Ozempic, Wegovy and Rybelsus all contain semaglutide. Mounjaro and Zepbound both contain tirzepatide. Our companion articles compared the two semaglutide products and the two tirzepatide products against each other; this one steps up a level and compares the molecules themselves. The headline finding from the first head-to-head weight-loss trial is clear — tirzepatide produces more weight loss — but “which is better” has a more nuanced answer than that single number suggests.

Two Molecules, Two Mechanisms

Semaglutide and tirzepatide both belong to the broad family of incretin-based therapies — drugs that mimic gut hormones involved in appetite and blood sugar — and both are given as a once-weekly injection under the skin. The difference is in how many hormone systems each one engages.

Semaglutide is a GLP-1 receptor agonist. It mimics a single gut hormone, GLP-1 (glucagon-like peptide-1), which slows stomach emptying, increases the sense of fullness and signals the brain to reduce appetite. It is the molecule in Ozempic, Wegovy and the oral semaglutide forms.

Tirzepatide is a dual agonist. It engages the GLP-1 receptor as well — but it also activates a second one, the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone involved in how the body handles glucose and fat. The working theory is that engaging both receptors at once produces a larger metabolic effect than GLP-1 alone, and the clinical results, covered below, are consistent with that. Tirzepatide is the molecule in Mounjaro and Zepbound.

That single mechanistic difference — one receptor versus two — is the root of almost everything that separates the two drugs.

At a glance, here is how the two molecules compare:

The Head-to-Head Trials

For years, comparing semaglutide and tirzepatide meant comparing separate trials with different participants — an unreliable exercise. That changed with SURMOUNT-5, the first head-to-head trial to test the two molecules directly against each other for weight loss.

SURMOUNT-5 enrolled 751 adults who had obesity, or overweight with a weight-related condition, and who did not have type 2 diabetes. Participants were randomly assigned to receive either tirzepatide or semaglutide, each titrated to the maximum dose the person could tolerate — 10 or 15 mg for tirzepatide, 1.7 or 2.4 mg for semaglutide — as a weekly injection over 72 weeks.

The result was decisive. Tirzepatide produced an average weight loss of 20.2% of body weight, against 13.7% for semaglutide — roughly 47% more mean weight loss. In absolute terms that was about 22.8 kg versus 15.0 kg. Tirzepatide also won on every key secondary measure: 31.6% of tirzepatide patients lost at least a quarter of their body weight, against 16.1% on semaglutide, and the reduction in waist circumference was larger as well. Tirzepatide was superior on the primary endpoint and on all key secondary endpoints.

A few honest caveats keep this in perspective. SURMOUNT-5 was funded by Eli Lilly, tirzepatide’s manufacturer — a standard arrangement for drug trials, and the results were published in a leading peer-reviewed journal, but worth knowing. It was also an open-label trial, meaning participants knew which drug they were receiving — a design limitation, though one that matters less for an objective measure like body weight than it would for a subjective outcome. And both drugs worked: a 13.7% average weight loss is a substantial, clinically meaningful result. The trial shows tirzepatide is more effective for weight loss, not that semaglutide is ineffective.

SURMOUNT-5 measured weight loss in adults without diabetes. The two molecules have also been compared head-to-head in type 2 diabetes, in the earlier SURPASS-2 trial — nearly 1,900 people with type 2 diabetes, where all three tirzepatide doses produced greater reductions in both blood sugar (HbA1c) and body weight than semaglutide. That comparison used semaglutide at 1 mg, a mid-range dose, but the direction matches SURMOUNT-5: across both the obesity and the diabetes evidence, tirzepatide’s dual mechanism delivers the larger effect.

Where Semaglutide Still Has the Edge

If SURMOUNT-5 were the whole story, the choice would be simple. It is not. Semaglutide retains two genuine advantages.

The first is cardiovascular evidence. Semaglutide has been studied for cardiovascular outcomes for longer and in more depth. The SELECT trial showed that semaglutide reduced the risk of major cardiovascular events in people with overweight or obesity and existing heart disease — and on the strength of it, Wegovy carries an FDA-approved cardiovascular indication. Ozempic carries cardiovascular and kidney-related indications in people with type 2 diabetes. Tirzepatide’s cardiovascular-outcomes trials are still running; as of 2026, neither Mounjaro nor Zepbound carries a cardiovascular risk-reduction indication. Tirzepatide may well earn one in time, but right now, if reducing cardiovascular risk is a documented priority, semaglutide has the established evidence.

The second is the oral option. Semaglutide exists in pill form — Rybelsus, oral Wegovy, and a newer oral Ozempic — for people who would rather not inject. Tirzepatide is currently injectable only; there is no FDA-approved oral tirzepatide. For someone with a strong preference against needles, that difference can matter more than a few percentage points of weight loss.

Neither of these makes semaglutide “better.” They make the choice depend on what you are optimizing for.

Side Effects, Tolerability, and Cost

The two molecules have broadly similar side-effect profiles. Both are dominated by gastrointestinal effects — nausea, diarrhea, vomiting, constipation — that are usually mild to moderate and concentrated during the weeks of dose escalation. Both carry the same class warnings, including a boxed warning about a risk of thyroid C-cell tumors seen in animal studies. Our guide to GLP-1 gastrointestinal side effects covers managing them.

There is a small signal worth noting. In SURMOUNT-5, gastrointestinal side effects severe enough to make people stop treatment were somewhat more common with semaglutide (5.6%) than tirzepatide (2.7%). But this should not be overread: large real-world studies have found that roughly 55% of patients stop either drug within a year, a similar rate for both. In everyday use, tolerability and the ability to stay on treatment look broadly comparable — tirzepatide’s efficacy advantage is not explained simply by people tolerating it better.

On cost, the brand-name drugs are in a similar range, with list prices running from roughly $1,000 to $1,350 a month before insurance and self-pay programs — our guide to GLP-1 costs without insurance breaks down the payment routes in detail. The two molecules also both exist as lower-cost compounded preparations through cash-pay telehealth — with one consistent difference: compounded tirzepatide generally costs more than compounded semaglutide, since tirzepatide is the more expensive molecule to source. Compounded forms of either are not FDA-approved, a trade-off covered in the note below.

Which Should You Take?

The honest framework is to start not with the molecule but with what matters most to you.

If maximum weight loss is the priority, the head-to-head evidence favors tirzepatide. It produced markedly more weight loss than semaglutide in a direct trial, and real-world data point the same way. For someone whose primary goal is the largest possible reduction in body weight, tirzepatide is the stronger choice on current evidence.

If documented cardiovascular risk reduction is a priority, semaglutide currently has the more established evidence base and the FDA indications to match. For a person whose heart health is a central concern, that track record carries weight.

If you want to avoid injections, semaglutide is the only one of the two available in an oral form.

And there is a practical factor that often outranks all of the above: what you can actually obtain and afford. The “better” molecule is of little use if your insurance covers the other one, or if only one is within reach at a price you can sustain. Coverage, supply and cost frequently decide this in practice, and there is no shame in that — a drug you can consistently take beats a marginally better one you cannot. This is a decision to make with a clinician who can weigh your weight-loss goals, your cardiovascular and metabolic picture, your tolerance for injections and your coverage together.

Frequently Asked Questions

Is tirzepatide better than semaglutide?

For weight loss, the head-to-head SURMOUNT-5 trial showed tirzepatide produced more — about 20% versus about 14%. But “better” depends on the goal: semaglutide has stronger cardiovascular-outcomes evidence and an oral form. Both are effective medicines.

What is the difference between semaglutide and tirzepatide?

Semaglutide acts on one gut-hormone receptor, GLP-1. Tirzepatide acts on two — GLP-1 and GIP. That dual mechanism is linked to its greater weight-loss effect. Semaglutide is the molecule in Ozempic and Wegovy; tirzepatide is the molecule in Mounjaro and Zepbound.

How much more weight loss does tirzepatide produce?

In SURMOUNT-5, the direct head-to-head trial, tirzepatide averaged 20.2% body-weight loss against 13.7% for semaglutide at 72 weeks — roughly 47% more mean weight loss. Both figures represent substantial, clinically meaningful results.

Is one safer than the other?

Their side-effect profiles are broadly similar — both gastrointestinal-dominant, both carrying the same class warnings. SURMOUNT-5 saw slightly more treatment-stopping gastrointestinal effects with semaglutide, but real-world discontinuation rates are similar for both. Neither is clearly safer.

Can I switch from semaglutide to tirzepatide?

Yes, and people do — often to pursue greater weight loss. But these are different molecules, not different doses of one drug, so a switch means starting tirzepatide’s own titration ladder from a low dose. It should be done with a prescriber, not improvised.

The Bottom Line

Semaglutide and tirzepatide are the two molecules behind the entire first generation of highly effective GLP-1 medicines, and they are genuinely different drugs — one acting on a single hormone receptor, the other on two. The first head-to-head trial settled the weight-loss question: tirzepatide produces more, by a clear margin. But weight loss is one outcome among several. Semaglutide has the deeper cardiovascular-outcomes evidence today and the only oral option, and in everyday practice the two are similarly tolerated.

So the realistic takeaway is not “tirzepatide wins” but “it depends on the goal.” Maximum weight loss favors tirzepatide; established cardiovascular protection and needle-free dosing favor semaglutide; and for many people, coverage and cost will decide it regardless. Both are effective medicines, and the right one is the one that fits your goals, your health profile and your circumstances — a judgment to reach with a clinician. For how the individual brands compare, see our guides to Ozempic versus Wegovy and Mounjaro versus Zepbound, or our full four-drug comparison.

This article is general information, not medical advice. Trial data, drug indications, prices and programs reflect the situation as of May 2026 and can change; confirm current details and discuss treatment with a qualified clinician.